Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome
Journal of Clinical Immunology · 2025
DOI: 10.1007/s10875-024-01828-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Anouk E M Nouwen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Netherton Syndrome, Pneumococcal Vaccines, Vaccines, Conjugate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency.
Methods
Vaccination responses in eight adult NS patients were assessed in a cross-sectional study performed between January and August 2022. Clinical patient data were retrospectively retrieved from electronic patient files. Immune responses to a polysaccharide Streptococcus pneumoniae vaccine (PPV23) and conjugate Haemophilus influenzae type b vaccine (ActHiB) were measured. SARS-CoV-2-specific (functional) antibody and T-cell responses following booster vaccination with an mRNA-based COVID-19 vaccine were compared to controls.
Results
None of the included patients suffered from recurrent and/or severe infections that could be attributed to a B- and/or T-cell immunodeficiency. ActHiB induced immune responses were normal in 7/7 NS patients. PPV23 induced responses were absent in 1/7, diminished in 2/7, and normal in 4/7 patients. Levels of SARS-CoV-2-specific binding and neutralizing antibodies after mRNA-based COVID-19 booster vaccination in NS patients were comparable to controls. SARS-CoV-2-specific CD4 + T-cell responses were detectable in all NS patients. In contrast, SARS-CoV-2-specific CD8 + T-cell responses were detectable in only 2/6 NS patients. T-cell responses to a positive control antigen pool were comparable to controls.
Conclusions
Vaccine-induced immune responses were detectable after polysaccharide, conjugate and mRNA-based vaccination in our cohort of NS patients. A spectrum of responsiveness to vaccine challenges was found, with the ranges of vaccine responses overlapping those demonstrated in healthy control populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Dermatology-Center of Pediatric Dermatology/Center of Rare Skin Diseases, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
- Department of Immunology, Erasmus University Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands. v.dalm@erasmusmc.nl.
- Department of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands. v.dalm@erasmusmc.nl.
Zitieren
APA
Nouwen, A. E. M., Zaeck, L. M., Schappin, R., Geers, D., Gommers, L., Bogers, S., Dik, W. A., Pasmans, S. G. M. A., GeurtsvanKessel, C. H., de Vries, R. D., & Dalm, V. A. S. H. (2025). Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01828-0
Vancouver
Nouwen AEM, Zaeck LM, Schappin R, Geers D, Gommers L, Bogers S, et al. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-024-01828-0
BibTeX
@article{Nouwen2025,
author = {Nouwen, Anouk E M and Zaeck, Luca M and Schappin, Renske and Geers, Daryl and Gommers, Lennert and Bogers, Susanne and Dik, Willem A and Pasmans, Suzanne G M A and GeurtsvanKessel, Corine H and de Vries, Rory D and Dalm, Virgil A S H},
title = {Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome},
journal = {Journal of Clinical Immunology},
year = {2025},
doi = {10.1007/s10875-024-01828-0}
}
EUVIMED